1. Pink Sheet
  2. >>Advanced Technologies
  3. >>Cell & Gene Therapies

Genome Editing: US FDA Eyes Platform-Based Approach To Development And Approval

 
• By Sue Sutter

CBER Director Peter Marks outlines a streamlined process to approval for treating different mutations of the same gene. NCATS’ Philip Brooks tells the Pink Sheet the approach avoids the need to “start from scratch for every new mutation.”

Diving platform
Genome editing poses special considerations for the platform approach to development and regulatory review. • Source: Shutterstock

The US Food and Drug Administration’s biologics center is considering ways to streamline the development and regulatory review of genome editing technology targeted at different mutations of the same gene.

The Center for Biologics Evaluation and Research “is working on developing a guidance on genome editing technology under the platform framework,” Julie Tierney, deputy center director for strategy, policy and...

Key Takeaways

  • CBER is developing guidance on how genome editing technology can leverage the platform framework.

  • The FDA could grant approval for treating all mutations in...

More from Cell & Gene Therapies

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

Keep Talking: US FDA’s Beleaguered Biologics Center Remains Vital To Regenerative Medicine

 
• By Bridget Silverman

Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.

Tougher Approval Standards May Follow Vinay Prasad’s Appointment To Lead US FDA’s CBER

 
• By Sarah Karlin-Smith

Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.

More from Conferences